Cognition Therapeutics, Inc. (CGTX) 10-Year Financial Performance & Capital Metrics

CGTX • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutCognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.Show more

Revenue $0
EBITDA -$54M -6.4%
Net Income -$34M -31.7%
EPS (Diluted) -0.85 +1.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -157.19% -97.3%
ROIC -
Debt/Equity 0.04 -14.2%
Interest Coverage -2158.64

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 91 (top 9%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 32.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM18.34%

EPS CAGR

10Y-

5Y-

3Y-

TTM50%

ROCE

10Y Avg-253.15%

5Y Avg-209.34%

3Y Avg-162.53%

Latest-244.82%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	81K	98K	0	235K	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	-81K	-98K	0	-235K	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-0.21%	1%	-	1%	-
Operating Expenses+	4.67M	17.31M	28.6M	43.32M	50.72M	53.97M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	3.45M	4.52M	10.03M	13.23M	13.53M	12.29M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	14.38M	12.89M	18.57M	30.32M	37.2M	41.68M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	-13.16M	-98K	0	-235K	0	0
Operating Income+	-17.83M	-17.41M	-28.6M	-43.55M	-50.72M	-53.97M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	0.02%	-0.64%	-0.52%	-0.16%	-0.06%
EBITDA+	-17.75M	-17.31M	-28.5M	-43.32M	-50.47M	-53.7M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	0.02%	-0.65%	-0.52%	-0.17%	-0.06%
D&A (Non-Cash Add-back)	81K	98K	93K	235K	252K	266K
EBIT	-3.82M	-6.09M	-10.82M	-21.37M	-25.76M	-33.95M
Net Interest Income+	12.14M	9.1M	16.55M	22.19M	27K	-25K
Interest Income	13.16M	10.86M	17.45M	22.22M	27K	0
Interest Expense	1.02M	1.75M	893K	28K	0	25K
Other Income/Expense	0	9.57M	16.88M	22.15M	24.94M	20M
Pretax Income+	-4.84M	-7.84M	-11.72M	-21.4M	-25.79M	-33.97M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	-22.15M	0	0
Effective Tax Rate %	1.44%	1.28%	1%	-0.04%	1%	1%
Net Income+	-6.95M	-10.07M	-11.72M	757K	-25.79M	-33.97M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-0.45%	-0.16%	1.06%	-35.07%	-0.32%
Net Income (Continuing)	-4.84M	-7.84M	-11.72M	757K	-25.79M	-33.97M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.32	-0.55	-0.73	-0.74	-0.86	-0.85
EPS Growth %	-	-0.72%	-0.33%	-0.01%	-0.16%	0.01%
EPS (Basic)	-0.32	-0.55	-0.73	-0.74	-0.86	-0.85
Diluted Shares Outstanding	21.94M	21.94M	22.23M	28.99M	30.03M	39.73M
Basic Shares Outstanding	21.94M	21.94M	22.23M	28.99M	29.99M	39.73M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	7.16M	6.91M	58.99M	47.65M	34.22M	29.55M
Cash & Short-Term Investments	2.89M	5.19M	54.72M	41.56M	29.92M	25.01M
Cash Only	2.89M	5.19M	54.72M	41.56M	29.92M	25.01M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	4.12M	1.15M	2.27M	3.67M	1.28M	2.69M
Days Sales Outstanding	-	-	-	-	-	-
Inventory	117K	0	0	0	0	0
Days Inventory Outstanding	527.22	-	-	-	-	-
Other Current Assets	-88K	23K	11K	0	3.02M	0
Total Non-Current Assets+	299K	211K	145K	2.78M	941K	679K
Property, Plant & Equipment	299K	211K	145K	1.05M	941K	679K
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	1.73M	0	0
Total Assets+	7.46M	7.12M	59.14M	50.42M	35.16M	30.23M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	-0.05%	7.31%	-0.15%	-0.3%	-0.14%
Total Current Liabilities+	3.68M	3.25M	7.86M	7.79M	10.17M	11.14M
Accounts Payable	2.36M	2M	4.17M	3.22M	3.69M	1.98M
Days Payables Outstanding	10.62K	7.46K	-	5K	-	-
Short-Term Debt	0	0	0	634K	544K	279K
Deferred Revenue (Current)	1000K	0	753K	1000K	1000K	1000K
Other Current Liabilities	-531K	985K	2.48M	870K	1.17M	1.53M
Current Ratio	1.94x	2.13x	7.50x	6.11x	3.37x	2.65x
Quick Ratio	1.91x	2.13x	7.50x	6.11x	3.37x	2.65x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	62.2M	72.05M	0	2.38M	520K	342K
Long-Term Debt	6.9M	12.85M	0	0	0	0
Capital Lease Obligations	0	0	0	695K	520K	342K
Deferred Tax Liabilities	0	0	0	-695K	0	0
Other Non-Current Liabilities	55.3M	59.2M	0	695K	0	0
Total Liabilities	65.88M	75.3M	7.86M	10.18M	10.69M	11.48M
Total Debt+	6.9M	12.85M	0	1.48M	1.24M	814K
Net Debt	4.01M	7.66M	-54.72M	-40.08M	-28.68M	-24.2M
Debt / Equity	-	-	-	0.04x	0.05x	0.04x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-17.41x	-9.94x	-32.02x	-1555.39x	-	-2158.64x
Total Equity+	-58.42M	-68.18M	51.27M	40.25M	24.47M	18.75M
Equity Growth %	-	-0.17%	1.75%	-0.22%	-0.39%	-0.23%
Book Value per Share	-2.66	-3.11	2.31	1.39	0.82	0.47
Total Shareholders' Equity	-58.42M	-68.18M	51.27M	40.25M	24.47M	18.75M
Common Stock	1K	1K	22K	29K	32K	60K
Retained Earnings	-58.24M	-68.22M	-94M	-115.4M	-141.19M	-175.16M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-185K	-187K	-198K	-199K	-195K	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.1M	-3.43M	-3.63M	-18.53M	-16.02M	-28.47M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-0.11%	-0.06%	-4.1%	0.14%	-0.78%
Net Income	-4.84M	-7.84M	-11.72M	-21.4M	-25.79M	-33.97M
Depreciation & Amortization	81K	98K	93K	235K	252K	266K
Stock-Based Compensation	361	0	5.18M	3.57M	4.35M	3.75M
Deferred Taxes	238K	0	0	0	0	0
Other Non-Cash Items	854.64K	1.24M	-33K	0	318K	195K
Working Capital Changes	570K	3.07M	2.84M	-943K	4.85M	1.29M
Change in Receivables	-1.12M	3M	-1.11M	-1.41M	2.39M	-1.41M
Change in Inventory	1.12M	0	0	0	0	0
Change in Payables	862K	-364K	2.17M	-1.09M	0	0
Cash from Investing+	-144K	-10K	-27K	-171K	-147K	-4K
Capital Expenditures	-144K	-10K	-27K	-171K	-147K	-4K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	2.79M	5.76M	53.2M	5.55M	4.52M	23.57M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	-34K	0	9.25M	1.62M	0	-46K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-3.24M	-3.44M	-3.66M	-18.7M	-16.16M	-28.48M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-0.06%	-0.06%	-4.11%	0.14%	-0.76%
FCF per Share	-0.15	-0.16	-0.16	-0.65	-0.54	-0.72
FCF Conversion (FCF/Net Income)	0.45x	0.34x	0.31x	-24.48x	0.62x	0.84x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-22.85%	1.65%	-79.69%	-157.19%
Return on Invested Capital (ROIC)	-	-	-	-19795.91%	-	-
Debt / Equity	-	-	-	0.04x	0.05x	0.04x
Interest Coverage	-17.41x	-9.94x	-32.02x	-1555.39x	-	-2158.64x
FCF Conversion	0.45x	0.34x	0.31x	-24.48x	0.62x	0.84x

Frequently Asked Questions

Growth & Financials

Cognition Therapeutics, Inc. (CGTX) grew revenue by 0.0% over the past year. Growth has been modest.

Cognition Therapeutics, Inc. (CGTX) reported a net loss of $28.0M for fiscal year 2024.

Dividend & Returns

Cognition Therapeutics, Inc. (CGTX) has a return on equity (ROE) of -157.2%. Negative ROE indicates the company is unprofitable.

Cognition Therapeutics, Inc. (CGTX) had negative free cash flow of $29.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener